argenx to Present at Upcoming Investor Conferences
May 31 2023 - 1:00AM
May 31,
2023Amsterdam,
the Netherlands – argenx (Euronext & Nasdaq: ARGX), a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases, today announced
that members of management will participate in two upcoming
investor conferences in June:
- William Blair 43rd
Annual Growth Stock Conference.
Presentation on Tuesday, June 6, 2023 at 1:20 p.m. CT in Chicago,
IL.
- Jefferies Healthcare
Conference. Fireside chat on Wednesday,
June 7, 2023 at 3:00 p.m. ET in New York, NY.
Additional information regarding these events will be available
on the Investors section of the argenx website at
argenx.com/investors.
About argenx
argenx is a global immunology company committed to improving the
lives of people suffering from severe autoimmune diseases.
Partnering with leading academic researchers through its Immunology
Innovation Program (IIP), argenx aims to translate immunology
breakthroughs into a world-class portfolio of novel antibody-based
medicines. argenx developed and is commercializing the
first-and-only approved neonatal Fc receptor (FcRn) blocker in the
U.S., Japan, the EU and the UK. The Company is evaluating
efgartigimod in multiple serious autoimmune diseases and advancing
several earlier stage experimental medicines within its therapeutic
franchises. For more information, visit www.argenx.com and follow
us on LinkedIn, Twitter, and Instagram.
For further information, please contact:
Media:
Erin Murphyemurphy@argenx.com
Investors:
Beth DelGiaccobdelgiacco@argenx.com
Lynn Eltonlelton@argenx.com
Argen X (EU:ARGX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Argen X (EU:ARGX)
Historical Stock Chart
From Aug 2023 to Aug 2024